ArticleFrontiers in immunology2025
Apolipoprotein M expression modifies the sphingolipid landscape in murine blood and lymph.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Members of the diverse family of sphingolipids (SPL), such as ceramides (Cer) and sphingomyelins (SM), are well-known structural and bioactive signaling molecules. A key SPL family member and critical signaling lipid, sphingosine 1-phosphate (S1P), is carried in blood primarily by its "chaperone" protein apolipoprotein M (ApoM) on high-density lipoprotein (HDL) particles. S1P has been shown to regulate diverse biological pathways through specific G protein-coupled receptor signaling (GPCR) that can be modulated based upon chaperone: ApoM or albumin. Blood concentrations of ApoM itself are altered in human diseases such as coronary artery disease, type I and II diabetes, and systemic lupus erythematosus, diseases that have also been linked to changes in other SPL species; however, studies measuring molecules only in blood while neglecting lymph concentrations may be excluding clues to the physiology affected by multiorgan metabolic pathways. Comparing SM, dihydroSM, Cer, dihydroCer, α-hydroxy Cer (αOHCer), Cer 1-phosphate (C1P), sphingosine (Sph)/dihydroSph, S1P/dihydroS1P, and diacylglycerol (DAG) concentrations in wild-type mouse blood and lymph plasmas with those in mice lacking ApoM and mice expressing a human transgene of ApoM, we describe unanticipated differences between the blood and lymph sphingolipidomes and their ApoM-responsive lipid species. Of the 100 unique SPL species targeted, 97 were identified in blood and 94 in lymph. Some of the most striking findings were in lymph, where we identified αOHCer as a previously unidentified major SPL constituent. This report provides a unique resource and starting point for further investigations into the contributions of the circulating sphingolipidome to homeostasis and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.